Cambridge, MA-based clinical research organization to manage Phase 1 acute myeloid leukemia study

CAMBRIDGE, MA, March 20, 2017 - PROMETRIKA, a boutique full service clinical research organization, is coordinating a Phase 1 trial for The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science. PROMETRIKA is responsible for the clinical trial management and site monitoring, medical monitoring, database implementation and data management, study drug management, pharmacovigilance, biostatistics, and medical writing. This trial is in acute myeloid leukemia (AML), which is a rare form of cancer with approximately 10,500 new cases each year in the United States.

“We are thrilled to work on this important trial alongside the institution in its pursuit to end cancer”, said Miganush Stepanians, Ph.D., President and CEO of PROMETRIKA.

As a CRO focused on both rare diseases and oncology, this study presents another opportunity for PROMETRIKA to leverage its considerable expertise and experience in AML in the ongoing fight against this devastating disease.

Share This Article